BMB Reports

생화학분자생물학회 (Korean Society for Biochemistry and Molecular Biology)
권호 표지
DOI QR코드

DOI QR Code

Highlighted STAT3 as a potential drug target for cancer therapy

  • Lee, Haeri (Department of Pharmacology and Biomedical Sciences, Seoul National University College of Medicine) ;
  • Jeong, Ae Jin (Department of Pharmacology and Biomedical Sciences, Seoul National University College of Medicine) ;
  • Ye, Sang-Kyu (Department of Pharmacology and Biomedical Sciences, Seoul National University College of Medicine)
  • 투고 : 2019.05.15
  • 발행 : 2019.07.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that regulates cell proliferation, differentiation, apoptosis, angiogenesis, inflammation and immune responses. Aberrant STAT3 activation triggers tumor progression through oncogenic gene expression in numerous human cancers, leading to promote tumor malignancy. On the contrary, STAT3 activation in immune cells cause elevation of immunosuppressive factors. Accumulating evidence suggests that the tumor microenvironment closely interacts with the STAT3 signaling pathway. So, targeting STAT3 may improve tumor progression, and anti-cancer immune response. In this review, we summarized the role of STAT3 in cancer and the tumor microenvironment, and present inhibitors of STAT3 signaling cascades.

키워드

참고문헌

  1. Hanahan D and Weinberg Robert A (2011) Hallmarks of Cancer: The Next Generation. Cell 144, 646-674 https://doi.org/10.1016/j.cell.2011.02.013
  2. Yu H and Jove R (2004) The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 4, 97-105 https://doi.org/10.1038/nrc1275
  3. Chen J, Wang J, Lin L et al (2012) Inhibition of STAT3 Signaling Pathway by Nitidine Chloride Suppressed the Angiogenesis and Growth of Human Gastric Cancer. Mol Cancer Ther 11, 277-287 https://doi.org/10.1158/1535-7163.MCT-11-0648
  4. Wang T, Niu G, Kortylewski M et al (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10, 48-54 https://doi.org/10.1038/nm976
  5. Huynh J, Chand A, Gough D and Ernst M (2019) Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map. Nat Rev Cancer 19, 82-96 https://doi.org/10.1038/s41568-018-0090-8
  6. Joyce JA and Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74-80 https://doi.org/10.1126/science.aaa6204
  7. Spill F, Reynolds DS, Kamm RD and Zaman MH (2016) Impact of the physical microenvironment on tumor progression and metastasis. Curr Opin Biotechnol 40, 41-48 https://doi.org/10.1016/j.copbio.2016.02.007
  8. Herrmann A, Kortylewski M, Kujawski M et al (2010) Targeting Stat3 in the Myeloid Compartment Drastically Improves the in vivo Antitumor Functions of Adoptively Transferred T Cells. Cancer Res 70, 7455-7464 https://doi.org/10.1158/0008-5472.CAN-10-0736
  9. Kortylewski M and Yu H (2008) Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol 20, 228-233 https://doi.org/10.1016/j.coi.2008.03.010
  10. Frank DA (2007) STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 251, 199-210 https://doi.org/10.1016/j.canlet.2006.10.017
  11. Roeser JC, Leach SD and McAllister F (2015) Emerging strategies for cancer immunoprevention. Oncogene 34, 6029 https://doi.org/10.1038/onc.2015.98
  12. Sonnenblick A, Shriki A, Galun E et al (2012) Tissue microarray-based study of patients with lymph nodepositive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis. Clin Transl Oncol 14, 232-236 https://doi.org/10.1007/s12094-012-0789-z
  13. Schaefer LK, Ren Z, Fuller GN and Schaefer TS (2002) Constitutive activation of $Stat3{\alpha}$ in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene 21, 2058-2065 https://doi.org/10.1038/sj.onc.1205263
  14. Geiger JL, Grandis JR and Bauman JE (2016) The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncology 56, 84-92 https://doi.org/10.1016/j.oraloncology.2015.11.022
  15. Li S, Priceman SJ, Xin H et al (2013) Icaritin Inhibits JAK/STAT3 Signaling and Growth of Renal Cell Carcinoma. PLoS One 8, e81657 https://doi.org/10.1371/journal.pone.0081657
  16. He G and Karin M (2010) NF-${\kappa}B$ and STAT3 - key players in liver inflammation and cancer. Cell Res 21, 159 https://doi.org/10.1038/cr.2010.183
  17. Saini U, Naidu S, ElNaggar AC et al (2016) Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene 36, 168 https://doi.org/10.1038/onc.2016.197
  18. Bar-Natan M, Nelson EA, Xiang M and Frank DA (2012) STAT signaling in the pathogenesis and treatment of myeloid malignancies. JAK-STAT 1, 55-64 https://doi.org/10.4161/jkst.20006
  19. Fukuda A, Wang Sam C, Morris John P et al (2011) Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression. Cancer Cell 19, 441-455 https://doi.org/10.1016/j.ccr.2011.03.002
  20. Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB and Tweardy DJ (2011) Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 117, 5701-5709 https://doi.org/10.1182/blood-2010-04-280123
  21. Alas S and Bonavida B (2003) Inhibition of Constitutive STAT3 Activity Sensitizes Resistant Non-Hodgkin's Lymphoma and Multiple Myeloma to Chemotherapeutic Drug-mediated Apoptosis. Clin Cancer Res 9, 316-326
  22. Yu H, Pardoll D and Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9, 798 https://doi.org/10.1038/nrc2734
  23. Bromberg J and Darnell JE (2000) The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19, 2468-2473 https://doi.org/10.1038/sj.onc.1203476
  24. Kim BH, Yi EH and Ye SK (2016) Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment. Arch Pharm Res 39, 1085-1099 https://doi.org/10.1007/s12272-016-0795-8
  25. Horiguchi A, Oya M, Marumo K and Murai M (2002) STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P. Kidney Int 61, 926-938 https://doi.org/10.1046/j.1523-1755.2002.00206.x
  26. Lin L, Liu A, Peng Z et al (2011) STAT3 Is Necessary for Proliferation and Survival in Colon Cancer-Initiating Cells. Cancer Res 71, 7226-7237 https://doi.org/10.1158/0008-5472.CAN-10-4660
  27. Corvinus FM, Orth C, Moriggl R et al (2005) Persistent STAT3 Activation in Colon Cancer Is Associated with Enhanced Cell Proliferation and Tumor Growth. Neoplasia 7, 545-555 https://doi.org/10.1593/neo.04571
  28. Catlett-Falcone R, Landowski TH, Oshiro MM et al (1999) Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells. Immunity 10, 105-115 https://doi.org/10.1016/S1074-7613(00)80011-4
  29. Epling-Burnette PK, Liu JH, Catlett-Falcone R et al (2001) Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107, 351-362 https://doi.org/10.1172/JCI9940
  30. Chen H, Yang Z, Ding C et al (2013) Discovery of O-Alkylamino-Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents. ACS Med Chem Lett 4, 180-185 https://doi.org/10.1021/ml3003082
  31. Kanai M, Konda Y, Nakajima T et al (2003) Differentiation-inducing factor-1 (DIF-1) inhibits STAT3 activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway. Oncogene 22, 548-554 https://doi.org/10.1038/sj.onc.1206109
  32. Pancotti F, Roncuzzi L, Maggiolini M and Gasperi-Campani A (2012) Caveolin-1 silencing arrests the proliferation of metastatic lung cancer cells through the inhibition of STAT3 signaling. Cell Signal 24, 1390-1397 https://doi.org/10.1016/j.cellsig.2012.02.015
  33. Wei D, Le X, Zheng L et al (2003) Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22, 319-329 https://doi.org/10.1038/sj.onc.1206122
  34. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H and Yu H (2008) Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118, 3367-3377 https://doi.org/10.1172/JCI35213
  35. Xu Q, Briggs J, Park S et al (2005) Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24, 5552-5560 https://doi.org/10.1038/sj.onc.1208719
  36. Jung JE, Lee HG, Cho IH et al (2005) STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J 19, 1296-1298 https://doi.org/10.1096/fj.04-3099fje
  37. Wojcik EJ, Sharifpoor S, Miller NA et al (2006) A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells. Oncogene 25, 2773-2784 https://doi.org/10.1038/sj.onc.1209306
  38. Cheng GZ, Zhang W, Sun M et al (2008) Twist Is Transcriptionally Induced by Activation of STAT3 and Mediates STAT3 Oncogenic Function. J Biol Chem 283, 14665-14673 https://doi.org/10.1074/jbc.M707429200
  39. Banerjee K and Resat H (2016) Constitutive activation of STAT3 in breast cancer cells: A review. Int J Cancer 138, 2570-2578 https://doi.org/10.1002/ijc.29923
  40. Wendt MK, Balanis N, Carlin CR and Schiemann WP (2014) STAT3 and epithelial-mesenchymal transitions in carcinomas. JAK-STAT 3, e28975-e28975 https://doi.org/10.4161/jkst.28975
  41. Chen M, Liu Y, Varley P et al (2015) High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21-Mediated Matrix Metalloproteinase Activity. Cancer Res 75, 1645-1656 https://doi.org/10.1158/0008-5472.CAN-14-2147
  42. Xiong H, Hong J, Du W et al (2012) Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J Biol Chem 287, 5819-5832 https://doi.org/10.1074/jbc.M111.295964
  43. Kalluri R (2003) Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3, 422-433 https://doi.org/10.1038/nrc1094
  44. Dechow TN, Pedranzini L, Leitch A et al (2004) Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci U S A 101, 10602-10607 https://doi.org/10.1073/pnas.0404100101
  45. Itoh M, Murata T, Suzuki T et al (2006) Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 25, 1195-1204 https://doi.org/10.1038/sj.onc.1209149
  46. Sano S, Itami S, Takeda K et al (1999) Keratinocytespecific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 18, 4657-4668 https://doi.org/10.1093/emboj/18.17.4657
  47. Silver DL, Naora H, Liu J, Cheng W and Montell DJ (2004) Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res 64, 3550-3558 https://doi.org/10.1158/0008-5472.CAN-03-3959
  48. Herbeuval J-P, Lelievre E, Lambert C, Dy M and Genin C (2004) Recruitment of STAT3 for Production of IL-10 by Colon Carcinoma Cells Induced by Macrophage-Derived IL-6. J Immunol 172, 4630-4636 https://doi.org/10.4049/jimmunol.172.7.4630
  49. Stumhofer JS, Silver JS, Laurence A et al (2007) Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 8, 1363 https://doi.org/10.1038/ni1537
  50. Saudemont A, Jouy N, Hetuin D and Quesnel B (2005) NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood 105, 2428-2435 https://doi.org/10.1182/blood-2004-09-3458
  51. Thakur R, Trivedi R, Rastogi N, Singh M and Mishra DP (2015) Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci Rep 5, 10194 https://doi.org/10.1038/srep10194
  52. Blaylock R (2015) Cancer microenvironment, inflammation and cancer stem cells: A hypothesis for a paradigm change and new targets in cancer control. Surg Neurol Int 6, 92 https://doi.org/10.4103/2152-7806.157890
  53. Liu X, He Z, Li C-H, Huang G, Ding C and Liu H (2012) Correlation analysis of JAK-STAT pathway components on prognosis of patients with prostate cancer. Pathol Oncol Res 18, 17-23 https://doi.org/10.1007/s12253-011-9410-y
  54. Wei W, Tweardy DJ, Zhang M et al (2014) STAT3 Signaling Is Activated Preferentially in Tumor-Initiating Cells in Claudin-Low Models of Human Breast Cancer. Stem Cells 32, 2571-2582 https://doi.org/10.1002/stem.1752
  55. Won C, Kim B-H, Yi EH et al (2015) Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. Hepatology 62, 1160-1173 https://doi.org/10.1002/hep.27968
  56. Zhang X, Hu F, Li G et al (2018) Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling. Cell Death Dis 9, 25 https://doi.org/10.1038/s41419-017-0176-3
  57. Haftchenary S, Luchman HA, Jouk AO et al (2013) Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma. ACS Med Chem Lett 4, 1102-1107 https://doi.org/10.1021/ml4003138
  58. Qu Y, Oyan AM, Liu R et al (2013) Generation of Prostate Tumor-Initiating Cells Is Associated with Elevation of Reactive Oxygen Species and IL-6/STAT3 Signaling. Cancer Res 73, 7090-7100 https://doi.org/10.1158/0008-5472.CAN-13-1560
  59. Hossain A, Gumin J, Gao F et al (2015) Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells 33, 2400-2415 https://doi.org/10.1002/stem.2053
  60. van der Zee M, Sacchetti A, Cansoy M et al (2015) IL6/JAK1/STAT3 Signaling Blockade in Endometrial Cancer Affects the $ALDH^{hi}/CD126^{+}$ Stem-like Component and Reduces Tumor Burden. Cancer Res 75, 3608-3622 https://doi.org/10.1158/0008-5472.CAN-14-2498
  61. Gibbs CP, Kukekov VG, Reith JD et al (2005) Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia (New York, N.Y.) 7, 967-976 https://doi.org/10.1593/neo.05394
  62. Marotta LLC, Almendro V, Marusyk A et al (2011) The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors. J Clin Invest 121, 2723-2735 https://doi.org/10.1172/JCI44745
  63. Zhao D, Pan C, Sun J et al (2014) VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene 34, 3107 https://doi.org/10.1038/onc.2014.257
  64. Tseng L-M, Huang P-I, Chen Y-R et al (2012) Targeting Signal Transducer and Activator of Transcription 3 Pathway by Cucurbitacin I Diminishes Self-Renewing and Radiochemoresistant Abilities in Thyroid Cancer-Derived $CD133^+$ Cells. J Pharmacol Exp Ther 341, 410-423 https://doi.org/10.1124/jpet.111.188730
  65. Groner B, Lucks P and Borghouts C (2008) The function of Stat3 in tumor cells and their microenvironment. Semin Cell Dev Biol 19, 341-350 https://doi.org/10.1016/j.semcdb.2008.06.005
  66. Jung JE, Kim HS, Lee CS et al (2008) STAT3 inhibits the degradation of HIF-$1{\alpha}$ by pVHL-mediated ubiquitination. Exp Mol Med 40, 479 https://doi.org/10.3858/emm.2008.40.5.479
  67. Samavati L, Rastogi R, Du W, Huttemann M, Fite A and Franchi L (2009) STAT3 tyrosine phosphorylation is critical for interleukin 1 beta and interleukin-6 production in response to lipopolysaccharide and live bacteria. Mol Immunol 46, 1867-1877 https://doi.org/10.1016/j.molimm.2009.02.018
  68. Gao H, Priebe W, Glod J and Banerjee D (2009) Activation of Signal Transducers and Activators of Transcription 3 and Focal Adhesion Kinase by Stromal Cell-Derived Factor 1 Is Required for Migration of Human Mesenchymal Stem Cells in Response to Tumor Cell-Conditioned Medium. Stem Cells 27, 857-865 https://doi.org/10.1002/stem.23
  69. Fujiwara Y, Takeya M and Komohara Y (2014) A novel strategy for inducing the antitumor effects of triterpenoid compounds: blocking the protumoral functions of tumor-associated macrophages via STAT3 inhibition. Biomed Res Int 2014, 348539 https://doi.org/10.1155/2014/348539
  70. Kim KJ, Kwon SH, Yun JH et al (2017) STAT3 activation in endothelial cells is important for tumor metastasis via increased cell adhesion molecule expression. Oncogene 36, 5445 https://doi.org/10.1038/onc.2017.148
  71. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H and Yu H (2008) Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118, 3367-3377 https://doi.org/10.1172/JCI35213
  72. Wu L, Du H, Li Y, Qu P and Yan C (2011) Signal transducer and activator of transcription 3 (Stat3C) promotes myeloid-derived suppressor cell expansion and immune suppression during lung tumorigenesis. Am J Pathol 179, 2131-2141 https://doi.org/10.1016/j.ajpath.2011.06.028
  73. Sun X, Sui Q, Zhang C, Tian Z and Zhang J (2013) Targeting Blockage of STAT3 in Hepatocellular Carcinoma Cells Augments NK Cell Functions via Reverse Hepatocellular Carcinoma-Induced Immune Suppression. Mol Cancer Ther 12, 2885-2896 https://doi.org/10.1158/1535-7163.MCT-12-1087
  74. Haura EB, Turkson J and Jove R (2005) Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2, 315-324 https://doi.org/10.1038/ncponc0195
  75. Debnath B, Xu S and Neamati N (2012) Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (Stat3) Protein. J Med Chem 55, 6645-6668 https://doi.org/10.1021/jm300207s
  76. Jinxia D, Fedora G and Nouri N (2007) Small Molecule Inhibitors of Stat3 Signaling Pathway. Curr Cancer Drug Targets 7, 91-107 https://doi.org/10.2174/156800907780006922
  77. Turkson J, Ryan D, Kim JS et al (2001) Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation. J Biol Chem 276, 45443-45455 https://doi.org/10.1074/jbc.M107527200
  78. Siddiquee KAZ, Gunning PT, Glenn M et al (2007) An Oxazole-Based Small-Molecule Stat3 Inhibitor Modulates Stat3 Stability and Processing and Induces Antitumor Cell Effects. ACS Chem Biol 2, 787-798 https://doi.org/10.1021/cb7001973
  79. Zhang X, Sun Y, Pireddu R et al (2013) A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant Transformation. Cancer Res 73, 1922-1933 https://doi.org/10.1158/0008-5472.CAN-12-3175
  80. Kumar A and Bora U (2012) Molecular docking studies on inhibition of Stat3 dimerization by curcumin natural derivatives and its conjugates with amino acids. Bioinformation 8, 988-993 https://doi.org/10.6026/97320630008988
  81. Shin D-S, Kim H-N, Shin KD et al (2009) Cryptotanshinone Inhibits Constitutive Signal Transducer and Activator of Transcription 3 Function through Blocking the Dimerization in DU145 Prostate Cancer Cells. Cancer Res 69, 193-202 https://doi.org/10.1158/0008-5472.CAN-08-2575
  82. Song H, Wang R, Wang S and Lin J (2005) A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A 102, 4700-4705 https://doi.org/10.1073/pnas.0409894102
  83. Schust J, Sperl B, Hollis A, Mayer TU and Berg T (2006) Stattic: A Small-Molecule Inhibitor of STAT3 Activation and Dimerization. Chem Biol 13, 1235-1242 https://doi.org/10.1016/j.chembiol.2006.09.018
  84. Fletcher S, Page BDG, Zhang X et al (2011) Antagonism of the Stat3-Stat3 Protein Dimer with Salicylic Acid Based Small Molecules. Chem Med Chem 6, 1459-1470 https://doi.org/10.1002/cmdc.201100194
  85. Lin Y-M, Wang C-M, Jeng J-C, Leprince D and Shih H-M (2013) HIC1 interacts with and modulates the activity of STAT3. Cell Cycle 12, 2266-2276 https://doi.org/10.4161/cc.25365
  86. Turkson J, Zhang S, Palmer J et al (2004) Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 3, 1533-1542
  87. Nagel-Wolfrum K, Buerger C, Wittig I, Butz K, Hoppe-Seyler F and Groner B (2004) The Interaction of Specific Peptide Aptamers With the DNA Binding Domain and the Dimerization Domain of the Transcription Factor Stat3 Inhibits Transactivation and Induces Apoptosis in Tumor Cells. Mol Cancer Res 2, 170-182
  88. Buerger C, Nagel-Wolfrum K, Kunz C et al (2003) Sequence-specific Peptide Aptamers, Interacting with the Intracellular Domain of the Epidermal Growth Factor Receptor, Interfere with Stat3 Activation and Inhibit the Growth of Tumor Cells. J Biol Chem 278, 37610-37621 https://doi.org/10.1074/jbc.M301629200
  89. Ge H, Liu H, Fu Z and Sun Z (2012) Therapeutic and Preventive Effects of an Epidermal Growth Factor Receptor Inhibitor on Oral Squamous Cell Carcinoma. J Int Med Res 40, 455-466 https://doi.org/10.1177/147323001204000207
  90. Huang C, Cao J, Huang KJ et al (2006) Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro. Cancer Sci 97, 1417-1423 https://doi.org/10.1111/j.1349-7006.2006.00340.x
  91. Ferrajoli A, Faderl S, Van Q et al (2007) WP1066 Disrupts Janus Kinase-2 and Induces Caspase-Dependent Apoptosis in Acute Myelogenous Leukemia Cells. Cancer Res 67, 11291-11299 https://doi.org/10.1158/0008-5472.CAN-07-0593
  92. Pardanani A, Hood J, Lasho T et al (2007) TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21, 1658 https://doi.org/10.1038/sj.leu.2404750
  93. Scuto A, Krejci P, Popplewell L et al (2010) The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia 25, 538 https://doi.org/10.1038/leu.2010.289
  94. Yan S, Li Z and Thiele CJ (2013) Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo. Oncotarget 4, 433-445 https://doi.org/10.18632/oncotarget.930
  95. Chen Z, Lee FY, Bhalla KN and Wu J (2006) Potent Inhibition of Platelet-Derived Growth Factor-Induced Responses in Vascular Smooth Muscle Cells by BMS-354825 (Dasatinib). Mol Pharmacol 69, 1527-1533 https://doi.org/10.1124/mol.105.020172
  96. Michels S, Trautmann M, Sievers E et al (2013) SRC Signaling Is Crucial in the Growth of Synovial Sarcoma Cells. Cancer Res 73, 2518-2528 https://doi.org/10.1158/0008-5472.CAN-12-3023
  97. Chang AY and Wang M (2013) Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells. BMC Cancer 13, 267 https://doi.org/10.1186/1471-2407-13-267
  98. Premkumar D, Jane E, Agostino N, Scialabba J and Pollack I (2010) Dasatinib synergizes with JSI-124 to inhibit growth and migration and induce apoptosis of malignant human glioma cells. J Carcinog 9, 7 https://doi.org/10.4103/1477-3163.65448
  99. Oyaizu T, Fung SY, Shiozaki A et al (2012) Src tyrosine kinase inhibition prevents pulmonary ischemia-reperfusioninduced acute lung injury. Intensive Care Med 38, 894-905 https://doi.org/10.1007/s00134-012-2498-z
  100. Antonarakis ES, Heath EI, Posadas EM et al (2013) A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology 71, 883-892 https://doi.org/10.1007/s00280-013-2079-z
  101. Gangadhar TC, Clark JI, Karrison T and Gajewski TF (2013) Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs 31, 769-773 https://doi.org/10.1007/s10637-012-9897-4
  102. Seltana A, Guezguez A, Lepage M, Basora N and Beaulieu JF (2013) Src family kinase inhibitor PP2 accelerates differentiation in human intestinal epithelial cells. Biochem Biophys Res Commun 430, 1195-1200 https://doi.org/10.1016/j.bbrc.2012.12.085
  103. Kim BH, Won C, Lee YH et al (2013) Sophoraflavanone G induces apoptosis of human cancer cells by targeting upstream signals of STATs. Biochem Pharmacol 86, 950-959 https://doi.org/10.1016/j.bcp.2013.08.009
  104. Aittomaki S and Pesu M (2014) Therapeutic Targeting of the JAK/STAT Pathway. Basic Clin Pharmacol Toxicol 114, 18-23 https://doi.org/10.1111/bcpt.12164
  105. Buchert M, Burns CJ and Ernst M (2015) Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene 35, 939 https://doi.org/10.1038/onc.2015.150
  106. Plimack ER, Lorusso PM, McCoon P et al (2013) AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. Oncologist 18, 819-820 https://doi.org/10.1634/theoncologist.2013-0198
  107. Furtek SL, Backos DS, Matheson CJ and Reigan P (2016) Strategies and Approaches of Targeting STAT3 for Cancer Treatment. ACS Chem Biol 11, 308-318 https://doi.org/10.1021/acschembio.5b00945
  108. Puls LN, Eadens M and Messersmith W (2011) Current status of SRC inhibitors in solid tumor malignancies. Oncologist 16, 566-578 https://doi.org/10.1634/theoncologist.2010-0408
  109. Nam S, Wen W, Schroeder A et al (2013) Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells. Mol Oncol 7, 369-378 https://doi.org/10.1016/j.molonc.2012.10.013
  110. Liu L, Gaboriaud N, Vougogianopoulou K et al (2014) MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells. Cancer Biol Ther 15, 178-184 https://doi.org/10.4161/cbt.26721